Please assess the completion status of the following clinical trial:

Trial Title: Reduction in YEllow Plaque by Aggressive Lipid LOWering Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient \> 18 years of age and willing to participate~* Stable patients who will undergo cardiac catheterization and PCI (intent to stent)~* Patient is willing to go on a cholesterol lowering medication for the duration of the study and willing to change statin therapy to the randomized statin therapy regardless of previous statin therapy and dose (e.g. Atorvastatin 80 mg) Patients that are screened for this study and are receiving another Statin such as Pravachol will be required to be willing to change their therapy to Rosuvastatin as per is randomization. If patients are receiving another statin, such as pravachol, or any other agent, and are at appropriate Lipid levels, they will be permitted to continue this therapy (if randomized to the standard therapy arm). There are a virtually unlimited number of possible scenarios for potential combination of all Lipid lowering agents at the time of enrollment that patients may be taking.~* Signed written Informed Consent~* Women of childbearing potential must agree to be on an acceptable method of birth control/contraceptive such as barrier method (condoms/diaphragm); hormonal contraceptives (birth control pills, implants (Norplant) or injections (Depo-Provera)); Intrauterine Device; or abstinence (no sexual activity).~* Fluency in English and/or Spanish~Exclusion Criteria:~* Patients who have acute myocardial infarction (Q wave or non-Q wave with CK-MB \> 5 times above the upper normal (31.5 ng/ml) within 72 hours)~* Patients who are in cardiogenic shock~* Patients with left main disease or restenotic lesions~* Patients with elevated CK-MB (\> 6.5 ng/ml) or Tnl (\> 0.5ng/L) at baseline~* Patients with platelet count \< 100,000 cell/mm3~* Patients who have co-morbidity which reduces life expectancy to one year~* Patients who are currently participating in another investigational drug/device study~* Patients with known hypersensitivity to HMG CO-A reductase therapy (statins)~* Patients with liver disease~* Patient with creatinine \> 2.0 mg/dL~* Pregnant women and women of childbearing potential who intend to have children during the duration of the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- standard of care lipid therapy (Type: ACTIVE_COMPARATOR): standard-care lipid-lowering therapy: Zocor or Lipitor
- aggressive lipid therapy (Type: EXPERIMENTAL): aggressive lipid therapy: Crestor

Based on this trial design, predict the completion outcome and termination type (if applicable).